Mabion has signed a deal with Novavax for the transfer of technology and technological trials in the manufacture of an antigen for Novavax's Covid-19 vaccine which is yet to be approved by the EU's medical agency, Mabion said in a Wednesday statement.
The state-owned Polish Development Fund (PFR) will offer PLN 40 mln (EUR 8.8 mln) to increase Mabion's capacity, Pawel Borys, head of the PFR, said on Twitter.
"Technology transfer (will take place) in the 2nd quarter. Poland will join a group of countries manufacturing a Covid-19 vaccine," Borys added.
Set up in 2007, Mabion focuses on the development and implementation of new generation biotech drugs. (PAP)